Brooks Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 533543 | NSE: BROOKS | Pharmaceuticals & Drugs | Small Cap

Brooks Laboratories Share Price

93.60 -0.70 -0.74%
as on 28-Mar'24 15:15

DeciZen - make an informed investing decision on Brooks Laboratories

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Brooks Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
492.06
Market Cap:
247.5 Cr.
52-wk low:
56.5
52-wk high:
185.2

Is Brooks Laboratories Ltd an attractive stock to invest in?

1. Is Brooks Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Brooks Laboratories Ltd is a below average quality company.

2. Is Brooks Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Brooks Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Brooks Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Brooks Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Brooks Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Brooks Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 6.7%7%9.3%1.8%-8.5%-9.3%-16.1%-13.5%1.1%-11.5%-
Value Creation
Index
-0.5-0.5-0.3-0.9-1.6-1.7-2.2-2.0-0.9-1.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 85.385.28057.555.75569.777.37755.574
Sales YoY Gr.--0.1%-6.1%-28.1%-3.2%-1.2%26.6%10.9%-0.4%-27.8%-
Adj EPS 3.73.95.40.9-7.1-7.7-9.4-6.30.1-3.30.2
YoY Gr.-4.3%39.9%-84.3%-929.4%NANANANA-2435.7%-
BVPS (₹) 55.656.862.365.458.450.839.525.726.122.826.4
Adj Net
Profit
7.27.610.61.7-13.8-15.1-23.4-15.70.3-8.20
Cash Flow from Ops. 10.72.18.19.6-6.2-5.1-9.4-0.93.10.6-
Debt/CF from Ops. 00.20.71.4-4.5-6.2-2.9-9.31.610.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -4.7%-0.1%-7.3%-27.8%
Adj EPS -198.6%NANA-2435.7%
BVPS-9.5%-17.2%-16.8%-12.7%
Share Price 20.6% 16.1% 18.8% 41.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
6.76.89.11.3-11.4-13.7-23-19.30.5-13.40.8
Op. Profit
Mgn %
108.113.98.8-16-15.2-3.71.32.4-10.43.7
Net Profit
Mgn %
8.58.913.22.9-24.8-27.4-33.6-20.30.4-14.70.7
Debt to
Equity
000.10.10.20.30.30.10.10.1-
Working Cap
Days
19318421622720823420616815922677
Cash Conv.
Cycle
35222527-77343129-4

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.80%

Sales growth is good in last 4 quarters at 24.64%

Sales growth has been subdued in last 3 years -7.29%

Latest Financials - Brooks Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 0.2 -5.4
TTM Sales (₹ Cr.) 74.4 74.4
BVPS (₹.) 26.4 30.4
Reserves (₹ Cr.) 43 53
P/BV 3.57 3.11
PE 492.06 0.00
From the Market
52 Week Low / High (₹) 56.50 / 185.15
All Time Low / High (₹) 10.32 / 185.15
Market Cap (₹ Cr.) 248
Equity (₹ Cr.) 26.3
Face Value (₹) 10
Industry PE 47.8

Management X-Ray of Brooks Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Brooks Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales85858058565570777756
Operating Expenses 77786952656374767561
Manufacturing Costs5543867874
Material Costs59615337393947484940
Employee Cost 3456101011121111
Other Costs 11976889986
Operating Profit 97115-9-8-412-6
Operating Profit Margin (%) 10.0%7.9%13.9%8.8%-16.0%-15.2%-5.6%1.2%2.4%-10.5%
Other Income 0220030110
Interest 0011233311
Depreciation 1112667712
Exceptional Items 0300000000
Profit Before Tax 810112-18-15-14-81-8
Tax 0101-4011700
Profit After Tax 79112-14-15-24-161-8
PAT Margin (%) 8.5%11.1%13.3%2.9%-24.8%-26.9%-35.0%-20.2%0.9%-14.7%
Adjusted EPS (₹)3.74.85.40.9-7.1-7.6-9.8-6.30.3-3.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 11211112212811410098646557
Share Capital 16161616161625252525
Reserves 9695106112988374404032
Minority Interest0000000000
Debt01613252824856
Long Term Debt00011171411100
Short Term Debt015291413756
Trade Payables16191618272726132623
Others Liabilities 4513-2-429787
Total Liabilities 1321361561581621571589310392

Fixed Assets

Gross Block252123127132132133202123
Accumulated Depreciation567281519568
Net Fixed Assets201616125124117113151515
CWIP 3753870100010
Investments 0001100474747
Inventories6878111014121711
Trade Receivables16191911101116101513
Cash Equivalents 302322232111
Others Assets23172512131414885
Total Assets 1321361561581621571589310392

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 112810-6-5-9-131
PBT 88112-18-15-14-81-8
Adjustment 1-113109121023
Changes in Working Capital 4-42621-8206
Tax Paid -2-2-5-2-1-10-400
Cash Flow From Investing Activity -11-1-14-17-51-2-110
Capex -2-11-34-17-61-2-110
Net Investments -68200000000
Others -3210000000
Cash Flow From Financing Activity 0047126101-40
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 00-1-1-3-3-3-3-1-1
Dividend Paid 0000000000
Others 0058149134-41
Net Cash Flow 01-1012-2000
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)6.868.599.111.33-11.38-13.83-24.62-19.171.03-13.45
ROCE (%)7.249.769.692.59-10.64-8.6-7.77-5.241.87-11.22
Asset Turnover Ratio0.650.640.550.410.360.350.440.620.780.57
PAT to CFO Conversion(x)1.570.220.735N/AN/AN/AN/A3N/A
Working Capital Days
Receivable Days82778783677271595891
Inventory Days24293240617162626992
Payable Days90106120170209249207151145222

Brooks Laboratories Ltd Stock News

Brooks Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Brooks Laboratories on 28-Mar-2024 15:15 is ₹93.60.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 15:15 the market cap of Brooks Laboratories stood at ₹247.5.
The latest P/E ratio of Brooks Laboratories as of 28-Mar-2024 15:15 is 492.1.
The latest P/B ratio of Brooks Laboratories as of 28-Mar-2024 15:15 is 3.57.
The 52-week high of Brooks Laboratories is ₹185.2 and the 52-week low is ₹56.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brooks Laboratories is ₹74.38 ( Cr.) .

About Brooks Laboratories Ltd

The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.

The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under “Revised Schedule M” of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.

Company’s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.

Product of the company

The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.

Some of the product categories are:

  • Beta Lactum
  • Cephalosporins
  • Carbapenems
  • General Injectable (Dry Powder)
  • General Injectable (Liquid)
  • Cortico Steroids
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.